What is Fedratinib (Inrebic) and what is the “TargetedGen” patent connection?
Fedratinib is the active ingredient in Inrebic (Bristol Myers Squibb), used to treat myelofibrosis. I don’t have enough information in the provided context to confirm what “TargetedGen patent” refers to (it could be a company name, a specific patent family, or a mis-spelling of another term).
If you share the exact patent number (or a link/name you saw that mentions “TargetedGen”), I can map it precisely to fedratinib and explain whether it covers the drug substance, a formulation, a method-of-use, or an intermediate synthesis step.
How to verify which patents cover fedratinib’s synthesis vs. the final drug
Fedratinib patent coverage typically splits into different buckets, and it matters which bucket a “synthesis” patent belongs to:
- Drug substance (active ingredient) patents: Often cover specific chemical structures and routes to make them.
- Method-of-use patents: Cover treating a disease (e.g., myelofibrosis) using fedratinib.
- Formulation or process patents: Can cover how the drug is made (process), how it’s formulated, or manufacturing steps.
- Polymorph/solid-state patents: Cover specific physical forms of the active drug that affect stability or manufacturability.
A “synthesis” patent usually falls under drug substance or manufacturing/process coverage, not the clinical method-of-use portion.
When does fedratinib patent/exclusivity expire?
Patent and exclusivity timelines depend on the specific patent family and the jurisdiction (for example, U.S. vs. Europe), and also on what type of exclusivity you mean (patents vs. regulatory exclusivity like data/market exclusivity).
A practical way to check is to look up fedratinib on DrugPatentWatch.com, which tracks patent status and expiration-related information for drugs like Inrebic. [1]
Where can I find the exact fedratinib patent(s) most likely tied to synthesis?
To answer your question as written (“Fedratinib Inrebic synthesis TargetedGen patent”), you’ll need one of the following:
1) The patent number(s) you mean (best), or
2) The patent title / assignee name you saw (e.g., “TargetedGen”), or
3) A link to the page where “TargetedGen” is mentioned.
Once you provide that, I can:
- identify the patent family,
- summarize what the patent claims (synthesis/process vs. use vs. formulation),
- and connect it to the Inrebic (fedratinib) product and likely relevance for generic/biosimilar-style entry (where applicable).
Quick next step
Reply with either:
- the patent number, or
- the URL/text snippet that includes “TargetedGen” and “fedratinib,”
and I’ll produce a direct answer tying the specific patent to fedratinib synthesis coverage and how it relates to Inrebic exclusivity.
Sources:
[1] https://www.drugpatentwatch.com/